The clinical utility of Memorial Symptom Assessment-Short Form and Condensed Memorial Symptom Assessment Scale in Turkish lung cancer patients
Clinical Respiratory Journal, cilt.9, sa.2, ss.221-227, 2015 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 9 Sayı: 2
- Basım Tarihi: 2015
- Doi Numarası: 10.1111/crj.12127
- Dergi Adı: Clinical Respiratory Journal
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.221-227
- Anahtar Kelimeler: cancer, Karnofsky scale, MSAS-Short Form, pulmonary, symptoms, TNM staging
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Introduction: Symptom assessment is essential in the palliative care of patients with cancer. We studied the Memorial Assessment Scale Test-Short Form (MSAS-SF) and Condensed Memorial Assessment Test (CMSAS) in Turkish lung cancer patients. Material and Method: Fifty-one patients with lung cancer (47 non-small, 4 small cell) were staged according to the International Association for the Study of Lung Cancer 2007 and filled the MSAS-SF. Karnofsky performance status, TNM staging, MSAS-SF and CMSAS scores were recorded. The study was approved by the local research ethics committee. Results: The mean age of 51 patients was 61.7±9. Fifty-one percent were staged as M1 while 49% were staged as M0. The mean values for global distress index, PHYS (physical symptom distress), PSYCH (psychological symptom score) and MSAS-SUM were 1.15±0.8, 0.9±0.8, 1.13±1.03 and 0.82±0.47 in order. The mean values for CPHYS (physical symptom distress for Condensed MSAS), CPSYCH (psychological symptom score for CMSAS) and CSUM (sum scores) were 1.2±0.75, 1.22±1.1 and 1.16±0.69 in order. Cronbach's alpha coefficients for MSAS-SF and CMSAS were 0.861 and 0.728 in order. Summary scores for both MSAS-SF and CMSAS-SF were significantly higher in patients with M1 disease than from M0 disease. In addition, PHYS and MSAS-SUM in MSAS-SF were significantly correlated with T and N stage. The area under curve for MSAS-SF and CMSAS were 0.793 and 0.70 in order. Conclusion: MSAS-SF and CMSAS demonstrated significantly higher scores in lung cancer patients with M1 disease than patients with M0 disease. Further studies are needed to evaluate the usefulness of MSAS-SF and CMSAS in lung cancer patients.